文献速递肿瘤 PET/CT核素与放射性配体治疗

高危非转移性前列腺癌患者新辅助化疗联合雄激素剥夺治疗疗效评估:[68Ga]Ga-PSMA-11 PET/CT、多参数MRI与前列腺特异性抗原的头对头前瞻性比较研究

Head-to-head comparisons of [68Ga]Ga-PSMA-11 PET/CT, multiparametric MRI, and prostate-specific antigen for the evaluation of therapeutic responses to neoadjuvant chemohormonal therapy in high-risk non-metastatic prostate cancer patients: a prospective study.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2022-11-22

该前瞻性研究纳入72例接受新辅助化疗联合雄激素剥夺治疗(NCHT)后行根治性前列腺切除术的高危非转移性前列腺癌患者,于治疗前后行PSA检测、[68Ga]Ga-PSMA-11 PET/CT及多参数MRI(mpMRI)。以术后病理为参照,[68Ga]Ga-PSMA-11 PET/CT(含EAU/EANM推荐标准与PERCIST 1.0标准)预测有利病理反应的敏感度、特异度、阳性似然比、阴性似然比、阳性预测值及阴性预测值均优于mpMRI和PSA谷值。

要点

  • 72例中24例(33.33%)获有利病理反应,含pCR 5例(6.94%)与MRD 19例(26.39%)。
  • [68Ga]Ga-PSMA-11 PET/CT预测有利病理反应的各项诊断效能指标均优于mpMRI和PSA谷值。
  • NCHT后根治术前SUVmax是NCHT有利病理反应的独立预测因素。

核心结论

  • 与PSA谷值和mpMRI相比,[68Ga]Ga-PSMA-11 PET/CT与NCHT有利病理反应的一致性更好。
  • 以[68Ga]Ga-PSMA-11 PET/CT作为疗效评估工具时,EAU/EANM推荐标准与PERCIST 1.0标准识别病理反应者的效能相当。

研究设计与样本

  • 前瞻性研究,纳入2021年6月至2022年3月接受NCHT后行根治性前列腺切除术的72例高危非转移性前列腺癌患者。
  • 所有患者于NCHT前后行PSA检测、[68Ga]Ga-PSMA-11 PET/CT及mpMRI扫描。
  • 采用PSA、RECIST 1.1、PERCIST 1.0及EAU/EANM推荐标准评估NCHT疗效,以术后病理结果为参照标准。
  • 有利病理反应定义为病理完全缓解(pCR)或微小残留病灶(MRD)。
  • 采用敏感度、特异度、阳性似然比、阴性似然比、阳性预测值、阴性预测值及Cohen kappa指数评估诊断准确性,并用逻辑回归分析确定[68Ga]Ga-PSMA-11 PET/CT衍生参数的独立预测价值。

主要发现

  • 所有病例NCHT后PSA水平均明显下降。
  • 24例(33.33%)获有利病理反应,其中pCR 5例(6.94%)、MRD 19例(26.39%)。
  • 按[68Ga]Ga-PSMA-11 PET/CT的EAU/EANM推荐标准20例(27.78%)为完全缓解(CR),PERCIST 1.0标准23例(31.94%)为CR。
  • EAU/EANM推荐标准与PERCIST 1.0标准呈强相关(Pearson R=0.857)。
  • 多因素逻辑回归分析显示,NCHT后根治性前列腺切除术前的最大标准化摄取值(SUVmax)是NCHT有利病理反应的独立预测因素。

关键数值与推荐

  • [68Ga]Ga-PSMA-11 PET/CT(EAU/EANM标准、PERCIST 1.0标准)预测有利病理反应的敏感度为75.00%、79.17%,特异度为95.83%、91.67%,阳性似然比为18.00、9.50,阴性似然比为0.26、0.23,阳性预测值为90.0%、82.6%,阴性预测值为88.5%、89.8%。
  • mpMRI与PSA谷值预测有利病理反应的敏感度为58.33%、58.33%,特异度为83.33%、68.75%,阳性似然比为3.50、1.87,阴性似然比为0.50、0.61,阳性预测值为63.6%、48.3%,阴性预测值为80.0%、76.7%。
  • 预测有利病理反应的kappa指数:PSA为0.257,RECIST 1.1为0.426,PERCIST 1.0为0.716,EAU/EANM推荐标准为0.739。

临床怎么用

  • 原文结论认为[68Ga]Ga-PSMA-11 PET/CT与NCHT有利病理反应的一致性优于PSA谷值和mpMRI。
  • [68Ga]Ga-PSMA-11 PET/CT作为疗效评估工具时,EAU/EANM推荐标准与PERCIST 1.0标准识别病理反应者的效能相当。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The optimal tool to evaluate the tumour therapeutic responses to neoadjuvant chemohormonal therapy (NCHT) in patients with high-risk non-metastatic prostate cancer (PCa) remains uncertain. We compared the role of [68Ga]-labeled prostate-specific membrane antigen (PSMA)-11 positron emission tomography/computerized tomography ([68Ga]Ga-PSMA-11 PET/CT), multiparametric MRI (mpMRI), and prostate-specific antigen (PSA) and assessed the practical value of the recent European Association of Urology and European Association of Nuclear Medicine (EAU/EANM) recommended criteria of PSMA PET/CT to evaluate the therapeutic responses to NCHT in patients with high-risk non-metastatic PCa. METHODS: This prospective study included 72 high-risk non-metastatic PCa patients receiving NCHT followed by radical prostatectomy from June 2021 to March 2022. PSA testing, [68Ga]Ga-PSMA-11 PET/CT, and mpMRI scanning were conducted in all patients before and after NCHT. Therapeutic responses to NCHT were evaluated with PSA, RECIST 1.1, PERCIST 1.0, and EAU/EANM recommended criteria. Postoperative pathological results were considered the reference standard. A favourable pathological response was defined as pathologic complete remission (pCR) or minimal residual disease (MRD). Diagnostic accuracy was assessed by sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), positive predictive value (PPV), negative predictive value (NPV), and Cohen's kappa index. Logistic regression analysis was used to determine the independent predictive value of [68Ga]Ga-PSMA-11 PET/CT-derived parameters. RESULTS: All cases experienced a marked decrease in PSA levels after NCHT. Twenty-four (33.33%) cases experienced a favourable pathological response, including five (6.94%) cases of pCR and 19 (26.39%) cases of MRD. According to the results of [68Ga]Ga-PSMA-11 PET/CT, EAU/EANM recommended criteria indicated that 20 (27.78%) cases had a CR, whereas PERCIST 1.0 criteria indicated that 23 (31.94%) cases had a CR. There was a strong association between EAU/EANM recommended criteria and PERCIST 1.0 criteria (Pearson's R=0.857). The sensitivity (75.00%, 79.17% vs. 58.33%, 58.33%), specificity (95.83%, 91.67% vs. 83.33%, 68.75%), PLR (18.00, 9.50 vs. 3.50, 1.87), NLR (0.26, 0.23 vs. 0.50, 0.61), PPV (90.0%, 82.6% vs. 63.6%, 48.3%), and NPV (88.5%, 89.8% vs. 80.0%, 76.7%) of [68Ga]Ga-PSMA-11 PET/CT (including EAU/EANM recommended criteria and PERCIST 1.0 criteria) to predict favourable pathological responses were all superior to those of mpMRI and nadir PSA. The kappa index to predict a favourable pathological response was 0.257 for PSA, 0.426 for RECIST 1.1, 0.716 for PERCIST 1.0, and 0.739 for EAU/EANM recommended criteria. Multivariate logistic analysis revealed that the post-NCHT maximum standardized uptake value (SUVmax) before radical prostatectomy was an independent predictor of a favourable pathological response to NCHT. CONCLUSIONS: [68Ga]Ga-PSMA-11 PET/CT had a better concordance with a favourable pathological response to NCHT compared with nadir PSA and mpMRI. EAU/EANM recommended criteria and PERCIST 1.0 criteria performed equally to identify pathological responders when [68Ga]Ga-PSMA-11 PET/CT was used as a therapeutic response assessment tool.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Ke ZB, Chen SM, Chen JY, et al. Head-to-head comparisons of [68Ga]Ga-PSMA-11 PET/CT, multiparametric MRI, and prostate-specific antigen for the evaluation of therapeutic responses to neoadjuvant chemohormonal therapy in high-risk non-metastatic prostate cancer patients: a prospective study. Eur J Nucl Med Mol Imaging. 2022. PMID: 36416906. doi:10.1007/s00259-022-06047-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。